NO993350D0 - Vitronectin-reseptor-antagonister - Google Patents

Vitronectin-reseptor-antagonister

Info

Publication number
NO993350D0
NO993350D0 NO993350A NO993350A NO993350D0 NO 993350 D0 NO993350 D0 NO 993350D0 NO 993350 A NO993350 A NO 993350A NO 993350 A NO993350 A NO 993350A NO 993350 D0 NO993350 D0 NO 993350D0
Authority
NO
Norway
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Application number
NO993350A
Other languages
English (en)
Other versions
NO993350L (no
Inventor
William H Miller
William E Bondinell
Thomas Wenfu Ku
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO993350D0 publication Critical patent/NO993350D0/no
Publication of NO993350L publication Critical patent/NO993350L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO993350A 1997-01-08 1999-07-07 Vitronectin-reseptor-antagonister NO993350L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3402697P 1997-01-08 1997-01-08
PCT/US1998/000490 WO1998030542A1 (en) 1997-01-08 1998-01-08 Vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
NO993350D0 true NO993350D0 (no) 1999-07-07
NO993350L NO993350L (no) 1999-09-06

Family

ID=21873846

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993350A NO993350L (no) 1997-01-08 1999-07-07 Vitronectin-reseptor-antagonister

Country Status (30)

Country Link
US (2) US6069158A (no)
EP (1) EP0977735B1 (no)
JP (1) JP2001508067A (no)
KR (1) KR20000069941A (no)
CN (1) CN1249745A (no)
AP (1) AP9901597A0 (no)
AR (1) AR010873A1 (no)
AT (1) ATE235467T1 (no)
AU (1) AU729641B2 (no)
BG (1) BG103548A (no)
BR (1) BR9806852A (no)
CA (1) CA2276738A1 (no)
CO (1) CO4920232A1 (no)
DE (1) DE69812602T2 (no)
DZ (1) DZ2395A1 (no)
EA (1) EA199900630A1 (no)
ES (1) ES2196534T3 (no)
HU (1) HUP0001945A3 (no)
ID (1) ID23168A (no)
IL (1) IL130760A0 (no)
MA (1) MA26462A1 (no)
NO (1) NO993350L (no)
NZ (1) NZ336560A (no)
OA (1) OA11076A (no)
PE (1) PE44799A1 (no)
PL (1) PL334499A1 (no)
SK (1) SK92799A3 (no)
TR (1) TR199901575T2 (no)
WO (1) WO1998030542A1 (no)
ZA (1) ZA9896B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514253A (ja) * 1997-09-04 2001-09-11 スミスクライン・ビーチャム・コーポレイション インテグリンレセプターアンタゴニスト
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
AR015446A1 (es) * 1997-09-19 2001-05-02 Smithkline Beecham Corp Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
KR20010042587A (ko) 1998-04-09 2001-05-25 기따자또 이찌로 인테그린 알파브이베타3 길항제로서 아미노피페리딘 유도체
JP4240424B2 (ja) * 1998-10-23 2009-03-18 エルジー ディスプレイ カンパニー リミテッド エッチング剤及びこれを用いた電子機器用基板の製造方法
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
CA2358855A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
DE19916837A1 (de) * 1999-04-14 2000-10-19 Merck Patent Gmbh Dibenzoazulenderivate
US6750219B1 (en) 1999-08-05 2004-06-15 Meiji Seika Kaisha, Ltd. Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2425117A1 (en) 2000-10-24 2002-05-23 Merck & Co., Inc. Dibenzoxazepine alpha v integrin receptor antagonist
JP4660067B2 (ja) 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血管新生剤とTNFαとを用いる組合せ療法
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
DK1734996T3 (da) * 2004-04-02 2013-06-10 Univ California Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP1888631B1 (de) 2005-05-31 2009-09-23 Ralf Jochem Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
ES2521679T3 (es) 2006-01-18 2014-11-13 Merck Patent Gmbh Terapia específica usando ligandos de integrinas para el tratamiento del cáncer
DK2101805T3 (da) 2007-01-18 2013-01-21 Merck Patent Gmbh Integrinligander til anvendelse i behandling af cancer
KR101595238B1 (ko) 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(sarm) 및 이의 용도
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
MX2011012491A (es) 2009-05-25 2011-12-14 Merck Patent Gmbh Administracion continua de cilengitida en tratamientos contra el cancer.
IN2012DN00303A (no) 2009-07-24 2015-05-08 Univ California
JP6649902B2 (ja) 2014-05-30 2020-02-19 ファイザー・インク 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794424A (fr) * 1972-01-24 1973-07-23 Science Union & Cie Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament
US3906032A (en) * 1972-11-10 1975-09-16 Squibb & Sons Inc Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof
IT1222986B (it) * 1987-10-23 1990-09-12 Texcontor Ets Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
ATE238996T1 (de) * 1995-06-29 2003-05-15 Smithkline Beecham Corp Integrin-rezeptor-antagonisten
JP2000502704A (ja) * 1995-12-29 2000-03-07 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
WO1999005107A1 (en) * 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
AR015446A1 (es) * 1997-09-19 2001-05-02 Smithkline Beecham Corp Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios

Also Published As

Publication number Publication date
EA199900630A1 (ru) 2000-02-28
CO4920232A1 (es) 2000-05-29
EP0977735A4 (en) 2000-04-05
DE69812602T2 (de) 2004-02-19
HUP0001945A3 (en) 2001-12-28
ATE235467T1 (de) 2003-04-15
JP2001508067A (ja) 2001-06-19
AU5912798A (en) 1998-08-03
OA11076A (en) 2003-03-13
PL334499A1 (en) 2000-02-28
US6069158A (en) 2000-05-30
ID23168A (id) 2000-03-23
ES2196534T3 (es) 2003-12-16
US6191304B1 (en) 2001-02-20
EP0977735B1 (en) 2003-03-26
AU729641B2 (en) 2001-02-08
KR20000069941A (ko) 2000-11-25
BR9806852A (pt) 2001-08-07
EP0977735A1 (en) 2000-02-09
SK92799A3 (en) 1999-12-10
CA2276738A1 (en) 1998-07-16
MA26462A1 (fr) 2004-12-20
ZA9896B (en) 1998-10-14
HUP0001945A2 (hu) 2000-10-28
IL130760A0 (en) 2001-01-28
TR199901575T2 (xx) 1999-11-22
DE69812602D1 (de) 2003-04-30
PE44799A1 (es) 1999-06-10
CN1249745A (zh) 2000-04-05
AP9901597A0 (en) 1999-09-30
DZ2395A1 (fr) 2003-06-04
NO993350L (no) 1999-09-06
AR010873A1 (es) 2000-07-12
BG103548A (en) 2000-11-30
WO1998030542A1 (en) 1998-07-16
NZ336560A (en) 2000-11-24

Similar Documents

Publication Publication Date Title
ATE312089T1 (de) Vitronektin rezeptor antagonisten
NO965608D0 (no) Vitronectin-reseptor-antagonister
NO993350D0 (no) Vitronectin-reseptor-antagonister
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
BR9612381A (pt) Antagonistas receptores vitronectina
NO983003D0 (no) Vitronectin-reseptor-antagonister
NO983002D0 (no) Vitronectin-reseptor-antagonister
NO20001100D0 (no) IL-8 reseptorantagonister
DE69833073D1 (de) CCR-3-Rezeptor-Antagonisten
NO20001407D0 (no) Vitronectin-reseptor-antagonister
ID24726A (id) Antagonis-antagonis reseptor trombin
NO20001514D0 (no) Vitronectin-reseptor-antagonist
NO20004503D0 (no) Vitronectin-reseptor-antagonister
NO20001515D0 (no) Vitronektin reseptor-antagonist
ATE381330T1 (de) Il-8 rezeptor-antagonisten
DZ2322A1 (fr) Antagonistes de récepteurs de vitronectine.
DE69920518D1 (de) Vitronectin rezeptor antagonist
DE69831413D1 (de) Il-8 rezeptor antagonisten
DE69824837D1 (de) Il-8-rezeptor-antagonisten
NO20021113D0 (no) Vitronectin-reseptor-antagonister
NO20010620D0 (no) Vitronektinreseptor-antagonister
DE69830671D1 (de) Integrin-rezeptor-antagonisten
DK1218005T3 (da) Vitronectinreptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application